Introduction Current guidelines and consensus statements have advised against the use of
direct oral anticoagulants (DOACs) for morbidly obese patients (BMI> 40 kg/m2), indicating …

Background Based on current guidelines and consensus documents, the use of direct oral
anticoagulants (DOACs) in obese patients (body mass index [BMI]> 30 kg/m2) is not …

Methods We systematically searched databases from their inception to October 3, 2023, to
review and examine the effectiveness and safety of DOACs compared to warfarin in patients …

Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …

Objectives Obesity is associated with increased risks of atrial fibrillation (AF) and venous
thromboembolism (VTE) for which anticoagulation is commonly used. However, data on the …

Introduction Atrial fibrillation (AF) is the most common arrhythmia, with an estimated
prevalence between 1–4%. On the other hand, obesity continued to be a prevalent health …

Highlights•Direct oral anticoagulants did not increase stroke or systemic embolism event
rate.•Direct oral anticoagulants had lower major bleeding rate than warfarin.•Direct oral …

In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …

Abstract Background and Aim Obesity affects nearly 650 million adults worldwide, and the
prevalence is steadily rising. This condition has significant adverse effects on cardiovascular …

Introduction: The safety and efficacy of direct oral anticoagulants (DOACs) compared to
vitamin K antagonists (VKAs) remain unknown in patients with BMI≥ 40 kg/m2. We aim to …